Results 191 to 200 of about 119,881 (373)
Abstract Intestinal failure‐associated liver disease occurs in 20% to 30% of patients with short bowel syndrome and intestinal failure (SBS‐IF). Apraglutide is a glucagon‐like peptide‐2 (GLP‐2) analog in clinical development for the treatment of patients with SBS‐IF.
Gerard Greig +4 more
wiley +1 more source
The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]
Choi, Jaebok +3 more
core +2 more sources
TNF-Inhibition With Etanercept For GVHD Prevention In Alternative Donor HCT: Lower TNFR1 Levels Correlate With Better Outcomes [PDF]
Sung Won Choi +19 more
openalex +1 more source
Chronic graft‐versus‐host disease in long‐term survivors of childhood leukemia
Abstract Hematopoietic stem cell transplantation (HSCT) is a curative treatment for high‐risk childhood leukemia but may lead to chronic graft‐versus‐host disease (cGvHD), a severe long‐term complication. This study analyzed data from the LEA cohort, including 446 childhood leukemia survivors treated with allogeneic HSCT.
Paul Saultier +25 more
wiley +1 more source
Eosinophilic Gastrointestinal Disease After Pediatric Organ and Bone Marrow Transplantation
ABSTRACT Background Previous studies have shown an increased prevalence of eosinophilic gastrointestinal disease (EGID) in pediatric liver and heart transplant recipients. However, EGID after other solid organ and bone marrow transplantations has not been extensively evaluated.
Erin Sinai +5 more
wiley +1 more source
Recipient mucosal-associated invariant T cells control GVHD within the colon
A. Varelias +21 more
semanticscholar +1 more source
ABSTRACT We investigated whether plasma cytomegalovirus (CMV) IL‐10 (cmvIL‐10) levels could serve as a biomarker of active CMV replication in allogeneic hematopoietic transplant recipients (allo‐HCT) in the presence or absence of letermovir (LMV) prophylaxis. A total of 189 leftover plasma samples that tested positive for CMV DNA (Alinity m CMV assay),
Ángela Sánchez‐Simarro +7 more
wiley +1 more source

